Project Grant R01AG093015
Award Date
6/1/25
Completion Date
3/31/30
Dollars Obligated
$792K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
The National Institute on Aging (NIA) awarded a $506,451 Project Grant under CFDA 93.866, the Aging Research federal grant program, to 3P Biotechnologies, Inc. The goal of this 1-year award is to develop an effective targeted delivery system for small interfering RNA (siRNA) therapeutics to mitigate neuroinflammatory diseases, such as Alzheimer's disease (AD). The key products or services to be delivered include: Optimizing the delivery of siRNA against the inflammatory regulator NF-kB (siNF-kB)...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 Aging Research) provides $120,734 to Trustees of Indiana University (IU Indianapolis) to investigate the role of the fractalkine axis, a key signaling pathway, in Alzheimer's disease pathology using human induced pluripotent stem cells. The central goal is to leverage human cell models to better understand how a specific genetic variant in the CX3CR1 receptor impacts microglial function and induces...
The National Institutes of Health (NIH), through the National Institute on Aging (NIA) Aging Research Federal Grant Program (CFDA 93.866), awarded a $2,217,438 Cooperative Agreement to the Trustees of Indiana University (IU Indianapolis) to optimize SHIP1 inhibitors for the treatment of Alzheimer's disease. The project aims to develop SHIP1 inhibitors that can improve microglial responses and promote neuroprotective phenotypes, potentially slowing cognitive decline. IU Indianapolis will...
The federal Project Grant award of $787,103.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) is supporting research at Vanderbilt University to develop a novel siRNA-lipid conjugate ("siRNA-EG18") for targeted gene silencing in brain myeloid cells, including microglia and macrophages, as a potential therapeutic approach for Alzheimer's disease. The research aims to comprehensively analyze the gene and protein silencing activity of siRNA-EG18 in brain myeloid...
This Project Grant award of $835,417, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop novel lipid nanoparticle (LNP) formulations to efficiently deliver nucleic acid therapeutics across the blood-brain barrier for the treatment of Alzheimer's disease (AD). The key objectives include: Synthesizing novel blood-brain barrier-crossing lipids and formulating a library of LNPs to optimize their trafficking across the blood-brain barrier. Engineering siRNA...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $479,375 to Florida International University to conduct research on the effects of a small molecule activator of autophagy, TPI-132, on insulin signaling, senescence, and neuropathology in mouse models of Alzheimer's disease. The key objectives are to: 1) optimize the potency and brain permeability of TPI-132 through medicinal chemistry, 2) evaluate the effects of TPI-132 and two optimized...
The National Institute on Aging (NIA) awarded a $1,994,202 Project Grant under CFDA 93.866 - Aging Research to Mayo Clinic Jacksonville (A Nonprofit Corporation) to research a new microglial therapy candidate for Alzheimer's disease (AD) that could prevent cognitive decline. The grant aims to target the tumor susceptibility gene 101 (TSG101) in microglia to manipulate extracellular vesicle secretion and mitigate tau pathology development. The research will be conducted in three phases: targeting...
This $3.38 million project grant from the National Institutes of Health's National Institute on Aging will fund research to repurpose FDA-approved agonists of the HCAR2 receptor as novel therapeutics for Alzheimer's disease. The grantee, Indiana University Iupui, will conduct preclinical studies using the 5XFAD mouse model of Alzheimer's disease to evaluate the therapeutic efficacy and pharmacological targets of the FDA-approved drugs niaspan and dimethyl fumarate in modulating microglial...
The federal Project Grant award R56AG085396, titled "Targeting P2RX7 Signaling as a Treatment for ADRD", is funded by the National Institute on Aging (CFDA 93.866 - Aging Research) for $792,498. The primary awardee, Trustees of Indiana University (doing business as Indiana University Indianapolis), will conduct research to investigate the role of P2X7 receptors in neuroinflammation and neurodegeneration associated with Alzheimer's disease and related dementias (ADRD). The project...
This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $4,694,672 to North Dakota State University from May 15, 2021 through April 30, 2024. The funding supports research to design a non-viral gene delivery system for delivering an APOE2 plasmid to the brain. Specifically, the university will synthesize and characterize liposomal nanoparticles loaded with chitosan-APOE2 polyplexes and modified with transferrin and cell-penetrating peptides...